Information Provided By: 
Fly News Breaks for June 5, 2019
HQY
Jun 5, 2019 | 06:47 EDT
JPMorgan analyst Anne Samuel lowered her price target for HealthEquity to $80 from $91 but maintains an Overweight rating on the name following the company's Q1 results. HealthEquity "continues to deliver," driving sales growth in excess of the market, Samuel tells investors in a research note. While the 2020 model is "somewhat constrained" by investments in future growth, the company is taking the right steps for long term share capture, says the analyst, who sees its 2021 EBITDA growth returning to ~30%.
News For HQY From the Last 2 Days
There are no results for your query HQY
